AI-generated summary
The authors report a case of a 61-year-old woman taking lenvatinib who developed a non-healing jaw ulcer with bone exposure after a tooth extraction, treated with five sessions of 635 nm diode laser photobiomodulation. They report pain relief after the first session, complete mucosal healing at one month, and no recurrence at six months. As a single case report, these findings cannot establish whether the treatment caused the healing.
- Participants
- 1
- Who or what was studied
- A single 61-year-old female patient with stage IV follicular thyroid carcinoma taking lenvatinib, with lenvatinib-related osteonecrosis of the jaw in the posterior right maxilla.
- Wavelengths
- 635 nm
- Limits stated in the abstract
- This is a single case report with one patient and no control group, so the outcomes cannot be attributed to the treatment.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction often presenting as a post-surgery complication that may interfere in the quality of the patient's life. In the last decade, additionally to bisphosphonates, other drugs have been associated with MRONJ including other antiresorptive, antiangiogenic or multitarget drugs such as levantinib. The data on MRONJ associated to lenvatinib is scarce with no guidelines for best management option. Our aim is to report a case of MRONJ associated with lenvatinib and the useful of a non-invasive management using local photobiomodulation (PBM) therapy with a 635nm diode laser.
Material And Methods
A 61-year-old female patient with a follicular thyroid carcinoma (stage IV) and taking lenvatinib presented to our Oral Medicine Unit with a painful non-healing ulcer with bone exposure, in the posterior right maxilla, after an extraction of a molar tooth which occurred 4 months previously. Bone rarefaction was detected in CT scan in the same affected area. We diagnosis a lenvatinib-related osteonecrosis of the Jaw (LRONJ). We performed 5 sessions of PBM treatment using a 635 nm diode laser, delivering 10J/ cm2 in affected area.
Results
At the end of the first session, a relief in the pain was already refereed by the patient. One month after, the oral mucosa was completely healed and tissue integrity was confirmed clinically and on panoramic radiograph and the patient referred an increase in her quality of life. On the last follow up after 6 months the patient was without any recurrence.
Conclusions
A lenvatinib-related osteonecrosis of the maxilla in a female patient is reported here for the first time. Moreover, a non-invasive management using PBM laser therapy has shown a successful healing of involved tissues and immediate symptoms relief improving the quality of life of the patient. Key words:Lenvatinib, MRONJ, osteonecrosis of the jaw, tyrosine kinase inhibitors, photobiomodulation.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635nm, 635 nm
- Energy density (fluence)
- 10J/ cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Case report. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.